Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS-8002 in Advanced Solid Tumors
NCT06832982Phase 1Recruiting
- Sponsor
- Shanghai Pushi Medical Science
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Fc Fusion Proteins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of FS-8002 in solid tumor, hepatocellular carcinoma (HCC), gastric adenocarcinoma and 2 more (3 arms), sponsored by Shanghai Pushi Medical Science. Primary endpoints: Maximum Tolerated Dose at 1.5 years, Recommended Phase 2 Dose at 1.5 years and 3 more. Started Feb 2025; status: recruiting.
02
Drugs
FS-8002
03
Conditions
solid tumorhepatocellular carcinoma (HCC)gastric adenocarcinomagastroesophageal junction adenocarcinomaglioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT06832982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832982.